Login to Your Account

Emcure's warning letter highlights ongoing data integrity issues in India

By T.V. Padma
Staff Writer

Wednesday, April 20, 2016

NEW DELHI – The U.S. FDA has rapped yet another Indian pharma company with a warning letter that drew attention to "significant violations of current good manufacturing practice (cGMP) regulations for finished pharmaceuticals."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription